RenovoRx (RNXT) Research & Development (2020 - 2026)
RenovoRx (RNXT) posted Research & Development of $1.2 million for Q1 2026, down 18.19% sequentially from $1.5 million in Q4 2025, and down 25.21% YoY from $1.6 million in Q1 2025.
RenovoRx (RNXT) Research & Development (2020 - 2026) Analysis & Trends
RenovoRx has reported Research & Development for 7 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Research & Development fell 25.21% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (down 8.89% YoY) and the FY2025 annual result came in at $6.3 million, up 4.05% from the prior year.
- Research & Development declined to $1.2 million in Q1 2026 per RNXT's latest filing, from $1.5 million in the prior quarter.
- Over five years, Research & Development peaked at $1.9 million in Q2 2023 and troughed at $775000.0 in Q4 2023.
- A 5-year average of $1.4 million and a median of $1.4 million in 2025 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 159.33% in 2022, down 29.52% in 2022.
- Over 5 years, Research & Development stood at $776000.0 in 2022, then declined by 0.13% to $775000.0 in 2023, then jumped by 103.35% to $1.6 million in 2024, then fell by 4.76% to $1.5 million in 2025, then decreased by 18.19% to $1.2 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.2 million, $1.5 million, and $1.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | RenovoRx | 61.96 Mn | 61.96 Mn | 766,000.00 | 1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Sep 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 1.58 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.54 Mn |
| Mar 31, 2024 | 1.26 Mn |
| Dec 31, 2023 | 775,000.00 |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 1.93 Mn |
| Mar 31, 2023 | 1.34 Mn |
| Dec 31, 2022 | 776,000.00 |
| Sep 30, 2022 | 846,000.00 |
| Jun 30, 2022 | 1.39 Mn |
| Mar 31, 2022 | 1.29 Mn |
| Dec 31, 2021 | 1.10 Mn |
| Sep 30, 2021 | 767,000.00 |